Failing the burden of evidence-based policymaking in making the proper case for breaking patents as the sole solution to lower drug prices in a complex healthcare market, [academics and activists] instead bootstrap the necessary policy and economic arguments by arguing that Congress has already approved of a price-control policy in two existing federal statutes.
[
add
]
[
|
|
...
]